Dark

Check out our Dark Pool Levels

CDTX
Cidara Therapeutics, Inc.
stock NASDAQ

Inactive

Jan 6, 2026

221.38USD+0.027%(+0.06)2,690,486

Pre-market

0.00USD-100.000%(-221.32)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 6, 2022

08:00AM EST Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing GlobeNewswire Inc

Dec 16, 2021

05:09PM EST 17:09 Thursday, December 16, 2021Wedbush (RTTNews) - Wedbush Reiterates Cidara Therapeutics, Inc. (CDTX) At Outperform With $6 Up From $5 Price Target RTTNews

Dec 14, 2021

07:20AM EST Cidara Therapeutics And Mundipharma Announce Topline Results From The Global Phase 3 Pivotal ReSTORE Trial Of Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis; Trial Met FDA And EMA-Pre-Specified Primary Endpoints Benzinga

07:03AM EST Cidara Therapeutics And Mundipharma Announce Positive Topline Results From The Global Phase 3 Pivotal ReSTORE Trial Of Rezafungin For The Treatment Of Candidemia And Invasive Candidiasis; Trial Met FDA And EMA-Pre-Specified Primary Endpoints Benzinga

07:00AM EST Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care GlobeNewswire Inc

06:57AM EST Galera Therapeutics, Cidara Therapeutics Shares Halted Pending News Benzinga

06:39AM EST Cidara Therapeutics Granted U.S. Patent #11,197,909 'Compositions and methods for the treatment of fungal infections' Benzinga

Nov 22, 2021

08:00AM EST Cidara Therapeutics Named A San Diego Metro Area Top Workplace For GlobeNewswire Inc

Nov 16, 2021

05:03AM EST Cidara Therapeutics CEO Jeffrey Stein Reported Purchase of 50,000 Shares @ Avg Price of $1.59/Share in Form 4 Filing on Monday Benzinga

Nov 10, 2021

06:07PM EST Cidara Therapeutics Q3 EPS $(0.37) Up From $(0.41) YoY, Sales $7.08M Up From $2.42M YoY Benzinga

Oct 13, 2021

04:01PM EDT Cidara Therapeutics Announces Closing of Concurrent Public GlobeNewswire Inc

Oct 8, 2021

09:13AM EDT Cidara Therapeutics Prices ~14.8M Share Offering At $1.55/Share Benzinga

09:13AM EDT Cidara Therapeutics Announces Pricing of Concurrent Public GlobeNewswire Inc

Oct 7, 2021

04:01PM EDT Cidara Therapeutics Begins Concurrent Common, Preferred Stock Offering, No Size Disclosed Benzinga

04:01PM EDT Cidara Therapeutics Announces Commencement of Concurrent Public GlobeNewswire Inc

Oct 1, 2021

04:11PM EDT Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing GlobeNewswire Inc

Sep 30, 2021

08:02AM EDT Antimicrobials Working Group Highlights Member Company Participation at IDWeek PR Newswire

Sep 29, 2021

08:00AM EDT Cidara Therapeutics to Present New Data for Rezafungin at TIMM GlobeNewswire Inc

Sep 27, 2021

08:00AM EDT Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021 GlobeNewswire Inc

Sep 22, 2021

12:29PM EDT Aegis Capital Maintains Buy on Cidara Therapeutics, Lowers Price Target to $8 Benzinga

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 Benzinga

06:12AM EDT WBB Securities Upgrades Cidara Therapeutics to Strong Buy Benzinga

Sep 7, 2021

08:00AM EDT Cidara Therapeutics to Participate in Two Upcoming Investor GlobeNewswire Inc

Sep 2, 2021

08:00AM EDT Virtual event will highlight the broad potential of the Cloudbreak platform and the commercial potential for rezafungin GlobeNewswire Inc

Sep 1, 2021

08:00AM EDT Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary. GlobeNewswire Inc

Aug 17, 2021

08:03AM EDT Cidara Therapeutics And Mundipharma Announce Completion Of Enrollment In Phase 3 ReSTORE Trial Of Rezafungin For Treatment Of Candidemia And Invasive Candidiasis Benzinga

08:00AM EDT Cidara Therapeutics and Mundipharma Announce Completion of GlobeNewswire Inc

Aug 12, 2021

05:22PM EDT Cidara Therapeutics Q2 EPS $0.18 Up From $(0.45) YoY, Sales $32.90M Up From $3.39M YoY Benzinga

Aug 5, 2021

08:02AM EDT Acurx Pharmaceuticals Joins the Antimicrobials Working Group PR Newswire

08:00AM EDT Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow GlobeNewswire Inc

Jul 29, 2021

10:29AM EDT Cidara Therapeutics Files For U.S. Patent Titled 'COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS' Benzinga

Jul 27, 2021

11:13AM EDT Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology Asia Congress Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 12, 2021

08:01AM EDT Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021 Benzinga

08:00AM EDT Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment ofcandidemia following one dose of rezafungin compared to multiple daily doses of standard of care GlobeNewswire Inc

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 7, 2021

08:09AM EDT Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RTTNews

08:00AM EDT Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing GlobeNewswire Inc

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jul 1, 2021

04:02PM EDT Cidara Therapeutics Names James Levine Has Resigned As CFO Benzinga

04:01PM EDT Cidara Therapeutics Provides Leadership Update GlobeNewswire Inc

Jun 30, 2021

08:00AM EDT Cidara Therapeutics to Present New Analyses for Rezafungin at the GlobeNewswire Inc

Jun 14, 2021

08:00AM EDT Cidara Therapeutics to Participate in the Raymond James Human GlobeNewswire Inc

Jun 8, 2021

11:19AM EDT Crestone Joins Antimicrobials Working Group PR Newswire

Jun 2, 2021

08:00AM EDT Cidara to Present at Mycology 2021 Conference GlobeNewswire Inc

May 13, 2021

05:35PM EDT Cidara Therapeutics Q1 EPS $(0.39) Up From $(0.46) YoY, Sales $2.40M Down From $2.53M YoY Benzinga

04:29PM EDT Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended March31, 2021 and provided an update on its corporate activities and product pipeline. GlobeNewswire Inc

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

Apr 7, 2021

08:00AM EDT Cidara Therapeutics to Present at the 20th Annual Needham Virtual GlobeNewswire Inc

Apr 5, 2021

08:05AM EDT Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza Candidates Benzinga

07:26AM EDT Janssen Pharma Gets Worldwide Rights To Cidara's CD388, RTTNews

07:07AM EDT Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza Benzinga

07:06AM EDT Cidara Therapeutics Enters Exclusive Worldwide License, Collaboration Agreement With Janssen RTTNews

07:00AM EDT Collaboration includes exclusive worldwide rights to Cidaras CD388 and other influenza Antiviral Conjugates (AVCs) for up to $780 million in upfront, milestone payments and R&D funding GlobeNewswire Inc

Apr 1, 2021

08:00AM EDT Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing GlobeNewswire Inc

Mar 4, 2021

11:57AM EST Aegis Capital Initiates Coverage On Cidara Therapeutics with Buy Rating, Announces Price Target of $9 Benzinga

Mar 3, 2021

08:00AM EST Cidara Therapeutics to Present at the H.C. Wainwright Global Life GlobeNewswire Inc

Feb 25, 2021

05:34PM EST Cidara Therapeutics Q4 EPS $(0.49) Down From $(0.42) YoY, Sales $3.70M Up From $1.81M YoY Benzinga

Feb 17, 2021

10:04AM EST UTILITY Therapeutics Joins Antimicrobials Working Group PR Newswire

08:04AM EST Cidara Therapeutics Announces New Data For Rezafungin At The 21st ICHS Symposium Benzinga

08:00AM EST Cidara Therapeutics Announces New Data for Rezafungin at the 21st GlobeNewswire Inc

Feb 11, 2021

08:00AM EST Cidara Therapeutics to Present New Data for Rezafungin and GlobeNewswire Inc

Jan 26, 2021

10:10AM EST Cidara Therapeutics shares were trading higher after the company announced an Orphan Drug Designation granted to its Rezafungin in the EU for the treatment of Invasive. Benzinga

08:14AM EST Cidara Therapeutics Inc Announces Orphan Drug Designation Granted To Rezafungin In EU For Treatment Of Invasive Candidiasis Benzinga

Jan 25, 2021

08:00AM EST Cidara Therapeutics Announces Key Additions to its Board of Directors GlobeNewswire Inc

Jan 5, 2021

04:59PM EST Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing GlobeNewswire Inc

Dec 15, 2020

08:00AM EST Cidara Therapeutics Appoints Biotechnology Industry Veteran GlobeNewswire Inc

Dec 1, 2020

08:06AM EST Cidara Therapeutics To Present Preclinical data For Flu Antiviral Conjugates At European Scientific Working Group on Influenza Conference Dec. 7-8 Benzinga

08:00AM EST Cidara Therapeutics to Present Preclinical Data for Influenza AVCs GlobeNewswire Inc

Nov 30, 2020

08:00AM EST Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present three posters at European Society of Intensive Care Medicine (ESICM) LIVES 2020, which takes placevirtually Dec. 6-9, 2020. GlobeNewswire Inc

Nov 16, 2020

08:00AM EST Cidara Therapeutics Named a San Diego Metro Area Top Workplace for GlobeNewswire Inc

Nov 12, 2020

11:58AM EST Insider Buys Cidara Therapeutics Stock Benzinga

Nov 11, 2020

04:05PM EST Cidara Therapeutics to Participate in Two Upcoming Investor GlobeNewswire Inc

Nov 5, 2020

05:04PM EST Cidara Therapeutics Q3 EPS $(0.41) Down From $0.08 YoY, Sales $2.40M Down From $19.10M YoY Benzinga

Oct 21, 2020

08:07AM EDT Cidara Therapeutics Announces New Clinical And Preclinical Data For Rezafungin And Influenza AVCs At IDWeek 2020 Oct. 21-25 Benzinga

08:00AM EDT Presentationshighlight clinical and preclinical progress of long-acting drug candidates for serious fungal and viral infections GlobeNewswire Inc

Oct 13, 2020

08:00AM EDT Cidara Therapeutics to Present at the 2020 American College of GlobeNewswire Inc

Sep 14, 2020

08:00AM EDT Cidara Therapeutics to Present New Clinical and Preclinical Data GlobeNewswire Inc

Sep 2, 2020

08:00AM EDT Cidara Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire Inc

Aug 26, 2020

07:07AM EDT Citigroup Maintains Buy on Cidara Therapeutics, Lowers Price Target to $5 Benzinga

Aug 13, 2020

04:55PM EDT Cidara Therapeutics Q2 EPS $(0.45) Up From $(0.47) YoY, Sales $3.39M Benzinga

04:49PM EDT Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June30, 2020, and provided an update on its corporate activities and product pipeline. GlobeNewswire Inc

Aug 4, 2020

08:00AM EDT Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020. GlobeNewswire Inc

Jul 27, 2020

08:00AM EDT Cidara Therapeutics Announces Formation of Scientific Advisory Board GlobeNewswire Inc

Jul 17, 2020

08:00AM EDT Cidara Therapeutics to Participate in B. Riley Virtual Summer GlobeNewswire Inc

Share